<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="review-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id>
<journal-title>Frontiers in Cell and Developmental Biology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell Dev. Biol.</abbrev-journal-title>
<issn pub-type="epub">2296-634X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">864257</article-id>
<article-id pub-id-type="doi">10.3389/fcell.2022.864257</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cell and Developmental Biology</subject>
<subj-group>
<subject>Mini Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>A Role for Liquid-Ordered Plasma Membrane Nanodomains Coordinating the Unconventional Secretory Pathway of Fibroblast Growth Factor 2?</article-title>
<alt-title alt-title-type="left-running-head">Lolicato and Nickel</alt-title>
<alt-title alt-title-type="right-running-head">Unconventional Secretion of FGF2</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Lolicato</surname>
<given-names>Fabio</given-names>
</name>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1714988/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Nickel</surname>
<given-names>Walter</given-names>
</name>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1418977/overview"/>
</contrib>
</contrib-group>
<aff>
<institution>Heidelberg University Biochemistry Center</institution>, <addr-line>Heidelberg</addr-line>, <country>Germany</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1239533/overview">Julien Villeneuve</ext-link>, Institute for Functional Genomics (CNRS), France</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/892215/overview">Bruno Beaumelle</ext-link>, UMR9004 Institut de Recherche en Infectiologie de Montpellier (IRIM), France</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Fabio Lolicato, <email>fabio.lolicato@bzh.uni-heidelberg.de</email>; Walter Nickel, <email>walter.nickel@bzh.uni-heidelberg.de</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Membrane Traffic, a section of the journal Frontiers in Cell and Developmental Biology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>01</day>
<month>04</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>10</volume>
<elocation-id>864257</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>01</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>02</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Lolicato and Nickel.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Lolicato and Nickel</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Fibroblast growth factor 2 (FGF2) is a tumor cell survival factor that belongs to a subgroup of extracellular proteins lacking N-terminal signal peptides. Whereas this phenomenon was already recognized in the early 1990s, detailed insights into the molecular mechanisms underlying alternative pathways of protein secretion from eukaryotic cells were obtained only recently. Today, we know about a number of alternative secretory mechanisms, collectively termed unconventional protein secretion (UPS). FGF2 belongs to a subgroup of cargo proteins secreted by direct translocation across the plasma membrane. This feature has been classified as type I UPS and is shared with other unconventionally secreted proteins, such as HIV-Tat and Tau. FGF2 translocation across the membrane is initiated through sequential interactions with the Na,K-ATPase, Tec kinase, and phosphoinositide PI(4,5)P<sub>2</sub> at the inner plasma membrane leaflet. Whereas the first two are auxiliary factors of this pathway, the interaction of FGF2 with PI(4,5)P<sub>2</sub> triggers the core mechanism of FGF2 membrane translocation. It is based on a lipidic membrane pore that is formed by PI(4,5)P<sub>2</sub>-induced oligomerization of FGF2. Membrane-inserted FGF2 oligomers are recognized as translocation intermediates that are resolved at the outer plasma membrane leaflet by glypican-1, a heparan sulfate proteoglycan that captures and disassembles FGF2 oligomers on cell surfaces. Here, we discuss recent findings suggesting the molecular machinery mediating FGF2 membrane translocation to be highly organized in liquid-ordered plasma membrane nanodomains, the core process underlying this unusual pathway of protein secretion.</p>
</abstract>
<kwd-group>
<kwd>fibroblast growth factor 2</kwd>
<kwd>unconventional protein secretion</kwd>
<kwd>protein self-translocation across membranes</kwd>
<kwd>lipidic membrane pores</kwd>
<kwd>phosphoinositides</kwd>
<kwd>heparan sulfates</kwd>
<kwd>glypican</kwd>
</kwd-group>
<contract-sponsor id="cn001">Deutsche Forschungsgemeinschaft<named-content content-type="fundref-id">10.13039/501100001659</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<sec id="s1-1">
<title>The Unconventional Secretory Pathway of FGF2</title>
<p>As with many cargo proteins transported into the extracellular space by various types of unconventional protein secretion (UPS) pathways (<xref ref-type="bibr" rid="B20">Malhotra, 2013</xref>; <xref ref-type="bibr" rid="B37">Rabouille, 2017</xref>; <xref ref-type="bibr" rid="B9">Dimou and Nickel, 2018</xref>; <xref ref-type="bibr" rid="B34">Pallotta and Nickel, 2020</xref>), fibroblast growth factor 2 (FGF2) is a growth factor involved in fundamental biological processes, such as angiogenesis and wound healing (<xref ref-type="bibr" rid="B4">Beenken and Mohammadi, 2009</xref>). These functions of FGF2 are linked to its ability to form ternary signaling complexes with heparan sulfates and FGF high affinity receptors on cell surfaces (<xref ref-type="bibr" rid="B35">Plotnikov et al., 1999</xref>; <xref ref-type="bibr" rid="B41">Schlessinger et al., 2000</xref>). In addition to its role in development, FGF2 also plays key roles under pathophysiological conditions with both cancer cells and cells from their microenvironment producing vast amounts of FGF2 to trigger tumor-induced angiogenesis (<xref ref-type="bibr" rid="B2">Akl et al., 2016</xref>). Under certain circumstances, signaling cascades initiated by FGF2 can trigger immune escape mechanisms that lead to a block of apoptotic programs (<xref ref-type="bibr" rid="B32">Noh et al., 2014</xref>). For example, FGF2 causes chemoresistance in patients suffering from acute myeloid leukemia (<xref ref-type="bibr" rid="B49">Traer et al., 2016</xref>; <xref ref-type="bibr" rid="B15">Javidi-Sharifi et al., 2019</xref>). Despite the requirement of FGF2 to have access to the extracellular space to activate FGF receptors on cell surfaces, the analysis of its primary structure revealed the absence of a signal peptide for ER/Golgi-dependent protein secretion. However, even though major efforts were made, the proposed existence of alternative pathways of protein secretion (<xref ref-type="bibr" rid="B24">Muesch et al., 1990</xref>; <xref ref-type="bibr" rid="B29">Nickel, 2003</xref>) remained a hypothesis for decades as detailed insights into the molecular mechanism by which FGF2 and other UPS cargoes are transported into the extracellular space could be obtained only recently (<xref ref-type="bibr" rid="B20">Malhotra, 2013</xref>; <xref ref-type="bibr" rid="B37">Rabouille, 2017</xref>; <xref ref-type="bibr" rid="B9">Dimou and Nickel, 2018</xref>; <xref ref-type="bibr" rid="B45">Steringer and Nickel, 2018</xref>; <xref ref-type="bibr" rid="B34">Pallotta and Nickel, 2020</xref>).</p>
<p>All components of the molecular machinery mediating unconventional secretion of FGF2 have been found to be localized to the plasma membrane (<xref ref-type="fig" rid="F1">Figure 1</xref>). These factors include the Na, K-ATPase (<xref ref-type="bibr" rid="B51">Zacherl et al., 2015</xref>; <xref ref-type="bibr" rid="B18">Legrand et al., 2020</xref>), Tec kinase containing a PH domain that binds to the phosphoinositide PI(3,4,5)P<sub>3</sub> (<xref ref-type="bibr" rid="B10">Ebert et al., 2010</xref>; <xref ref-type="bibr" rid="B17">La Venuta et al., 2016</xref>; <xref ref-type="bibr" rid="B44">Steringer et al., 2012</xref>) as well as PI(4,5)P<sub>2</sub>, another phosphoinositide enriched in the inner leaflet of the plasma membrane (<xref ref-type="bibr" rid="B30">Nickel, 2011</xref>; <xref ref-type="bibr" rid="B46">Temmerman et al., 2008</xref>; <xref ref-type="bibr" rid="B47">Temmerman and Nickel, 2009</xref>). A cluster of amino acids with basic side chains (K127, R128, and K133; <xref ref-type="fig" rid="F1">Figure 1</xref>) mediates PI(4,5)P<sub>2</sub>-dependent membrane recruitment of FGF2 (<xref ref-type="bibr" rid="B46">Temmerman et al., 2008</xref>; <xref ref-type="bibr" rid="B43">Steringer et al., 2017</xref>; <xref ref-type="bibr" rid="B25">M&#xfc;ller et al., 2015</xref>). This interaction initiates the core mechanism of FGF2 membrane translocation, a process that involves membrane insertion of FGF2 oligomers (<xref ref-type="bibr" rid="B45">Steringer and Nickel, 2018</xref>; <xref ref-type="bibr" rid="B44">Steringer et al., 2012</xref>; <xref ref-type="bibr" rid="B43">Steringer et al., 2017</xref>). Their biogenesis depends on the formation of intermolecular disulfide bridges (<xref ref-type="bibr" rid="B9">Dimou and Nickel, 2018</xref>; <xref ref-type="bibr" rid="B43">Steringer et al., 2017</xref>; <xref ref-type="bibr" rid="B25">M&#xfc;ller et al., 2015</xref>). As illustrated in <xref ref-type="fig" rid="F1">Figure 1</xref>, the lipidic membrane pore that is induced by FGF2 oligomers is characterized by a toroidal architecture (<xref ref-type="bibr" rid="B44">Steringer et al., 2012</xref>; <xref ref-type="bibr" rid="B25">M&#xfc;ller et al., 2015</xref>; <xref ref-type="bibr" rid="B45">Steringer and Nickel, 2018</xref>). Several experimental observations support this view, such as the simultaneous membrane passage of fluorescent tracers and the transbilayer diffusion of membrane lipids that can be observed concomitant with PI(4,5)P<sub>2</sub>-dependent membrane insertion of FGF2 oligomers (<xref ref-type="bibr" rid="B44">Steringer et al., 2012</xref>; <xref ref-type="bibr" rid="B45">Steringer and Nickel, 2018</xref>). Furthermore, diacylglycerol, a cone-shaped lipid that interferes with PI(4,5)P<sub>2</sub>-induced positive membrane curvature inhibits membrane pore formation by FGF2 oligomers (<xref ref-type="bibr" rid="B44">Steringer et al., 2012</xref>; <xref ref-type="bibr" rid="B45">Steringer and Nickel, 2018</xref>). Finally, fusion proteins, such as FGF2-GFP form lipidic membrane pores with an increased pore size cutoff, a phenomenon that is reported previously for toroidal membrane pores (<xref ref-type="bibr" rid="B13">Gilbert et al., 2014</xref>). Therefore, PI(4,5)P<sub>2</sub> plays multiple roles in FGF2 secretion with 1) mediating FGF2 membrane recruitment, 2) initiating FGF2 oligomerization, and 3) stabilizing positive membrane curvature to trigger the conversion of the lipid bilayer into a toroidal membrane pore with membrane-inserted FGF2 oligomers accommodated in its hydrophilic center (<xref ref-type="bibr" rid="B9">Dimou and Nickel, 2018</xref>; <xref ref-type="bibr" rid="B45">Steringer and Nickel, 2018</xref>). In this context, because FGF2 can attract multiple PI(4,5)P<sub>2</sub> molecules, a strong local accumulation of this bilayer perturbing membrane lipid is proposed to compromise the integrity of the plasma membrane facilitating a membrane remodeling process converting the lipid bilayer into a toroidal membrane pore (<xref ref-type="bibr" rid="B43">Steringer et al., 2017</xref>; <xref ref-type="bibr" rid="B9">Dimou and Nickel, 2018</xref>; <xref ref-type="bibr" rid="B34">Pallotta and Nickel, 2020</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>The unconventional secretory pathway of FGF2. Localization, molecular machinery, and mechanism as well as <italic>cis</italic> elements in FGF2 that are required for FGF2 translocation across the plasma membrane of eukaryotic cells. Whereas it is clear that the Na,K-ATPase are upstream of PI(4,5)P<sub>2</sub>, the order of sequential FGF2 interactions with the Na,K-ATPase and Tec kinase remains to be determined. It is also unclear whether FGF2 is secreted as a phosphorylated protein or whether a phosphatase removes this modification before FGF2 membrane translocation occurs.</p>
</caption>
<graphic xlink:href="fcell-10-864257-g001.tif"/>
</fig>
<p>Based on the findings described above, membrane-inserted FGF2 oligomers are believed to be membrane translocation intermediates as part of an assembly/disassembly pathway that drives directional transport of FGF2 into the extracellular space (<xref ref-type="bibr" rid="B9">Dimou and Nickel, 2018</xref>; <xref ref-type="bibr" rid="B45">Steringer and Nickel, 2018</xref>). The final step of this process is mediated by cell surface heparan sulfate proteoglycans that capture FGF2 at the outer leaflet of the plasma membrane (<xref ref-type="bibr" rid="B31">Nickel, 2007</xref>; <xref ref-type="bibr" rid="B27">Nickel and Rabouille, 2009</xref>; <xref ref-type="bibr" rid="B28">Nickel and Seedorf, 2008</xref>; <xref ref-type="bibr" rid="B52">Zehe et al., 2006</xref>). Of note, compared with PI(4,5)P<sub>2</sub>, heparan sulfates exhibit an approximately hundredfold higher affinity toward FGF2 (<xref ref-type="bibr" rid="B46">Temmerman et al., 2008</xref>; <xref ref-type="bibr" rid="B47">Temmerman and Nickel, 2009</xref>; <xref ref-type="bibr" rid="B43">Steringer et al., 2017</xref>; <xref ref-type="bibr" rid="B38">Raman et al., 2003</xref>). Furthermore, the binding site in FGF2 for heparan sulfates and PI(4,5)P<sub>2</sub> overlaps with some key residues, such as K133 being essential for both types of interactions (<xref ref-type="bibr" rid="B46">Temmerman et al., 2008</xref>; <xref ref-type="bibr" rid="B47">Temmerman and Nickel, 2009</xref>; <xref ref-type="bibr" rid="B43">Steringer et al., 2017</xref>). Consistently, interactions of FGF2 with heparan sulfate chains and PI(4,5)P<sub>2</sub> are shown to be mutually exclusive (<xref ref-type="bibr" rid="B43">Steringer et al., 2017</xref>). These findings reveal a key aspect of the molecular mechanism of FGF2 membrane translocation providing a compelling explanation of how FGF2 assembles at the inner leaflet in a PI(4,5)P<sub>2</sub>-dependent manner into membrane-inserted oligomers that are captured and disassembled at the outer leaflet by cell surface heparan sulfate chains (<xref ref-type="bibr" rid="B9">Dimou and Nickel, 2018</xref>; <xref ref-type="bibr" rid="B34">Pallotta and Nickel, 2020</xref>; <xref ref-type="bibr" rid="B37">Rabouille, 2017</xref>). Thus, heparan sulfates mediate the last step of FGF2 membrane translocation with FGF2 being retained on cell surfaces (<xref ref-type="fig" rid="F1">Figure 1</xref>). Following translocation into the extracellular space, FGF2 is capable of spreading to neighboring cells, probably mediated by direct exchange between heparan sulfate chains that are linked to proteoglycans on cell surfaces that are in close proximity (<xref ref-type="bibr" rid="B52">Zehe et al., 2006</xref>). Thus, from the biosynthesis of FGF2 on free ribosomes all the way to the cell surface, heparan sulfate proteoglycans exert multiple functions with 1) mediating the final step of FGF2 secretion (<xref ref-type="bibr" rid="B31">Nickel, 2007</xref>; <xref ref-type="bibr" rid="B52">Zehe et al., 2006</xref>), 2) protecting FGF2 on cell surfaces against degradation and denaturation (<xref ref-type="bibr" rid="B33">Nugent and Iozzo, 2000</xref>) and 3) mediating FGF2 signaling through ternary complexes in which FGF2, heparan sulfate chains, and FGF high-affinity receptors are engaged (<xref ref-type="bibr" rid="B36">Presta et al., 2005</xref>; <xref ref-type="bibr" rid="B5">Belov and Mohammadi, 2013</xref>; <xref ref-type="bibr" rid="B40">Ribatti et al., 2007</xref>). In conclusion, directional transport of FGF2 into the extracellular space depends on sequential interactions of FGF2 with PI(4,5)P<sub>2</sub> at the inner leaflet and, bridged my membrane translocation intermediates, interactions with heparan sulfates on the cell surface (<xref ref-type="fig" rid="F1">Figure 1</xref>). The proposed mechanism is further supported by previous studies demonstrating that FGF2 remains in a fully folded state during all steps of its unconventional secretory route (<xref ref-type="bibr" rid="B3">Backhaus et al., 2004</xref>; <xref ref-type="bibr" rid="B48">Torrado et al., 2009</xref>; <xref ref-type="bibr" rid="B30">Nickel, 2011</xref>), a phenomenon that reflects the requirement for the formation of defined oligomers during membrane insertion. These findings imply a quality control step that ensures secretion to be limited to FGF2 species that are biologically active (<xref ref-type="bibr" rid="B48">Torrado et al., 2009</xref>; <xref ref-type="bibr" rid="B30">Nickel, 2011</xref>).</p>
<p>Another aspect of quality control as part of the unconventional secretory pathway of FGF2 might be related to the role of the Na, K-ATPase in this process. Whereas its function may be restricted to building a landing platform as the first contact point of FGF2 at the inner plasma membrane leaflet (<xref ref-type="bibr" rid="B18">Legrand et al., 2020</xref>), it is also speculated that unconventional secretion of FGF2 could be linked to the regulation of the ATPase activity of the Na,K-ATPase (<xref ref-type="bibr" rid="B34">Pallotta and Nickel, 2020</xref>). Because FGF2 secretion involves the formation of a transient lipidic pore in the plasma membrane and FGF2 binds to a region in the cytoplasmic domain of the <italic>&#x3b1;</italic>-subunit of the Na,K-ATPase that contains its enzymatic activity (<xref ref-type="bibr" rid="B18">Legrand et al., 2020</xref>), it appears to be an intriguing hypothesis that FGF2 might upregulate the ATPase activity of this Na,K exchanger. This, in turn, might help to maintain the membrane potential under circumstances that trigger the formation of lipidic membrane pores during unconventional secretion of FGF2, a process that does not appear to compromise cell viability (<xref ref-type="bibr" rid="B9">Dimou and Nickel, 2018</xref>; <xref ref-type="bibr" rid="B45">Steringer and Nickel, 2018</xref>; <xref ref-type="bibr" rid="B34">Pallotta and Nickel, 2020</xref>).</p>
<p>The molecular mechanism illustrated in <xref ref-type="fig" rid="F1">Figure 1</xref> is also relevant for other unconventionally secreted proteins. For example, HIV-Tat and Tau are shown to directly translocate across plasma membranes to get access to the extracellular space. Like FGF2, these processes require physical interactions with PI(4,5)P<sub>2</sub> at the inner leaflet and heparan sulfates at the outer leaflet of the plasma membrane (<xref ref-type="bibr" rid="B39">Rayne et al., 2010</xref>; <xref ref-type="bibr" rid="B7">Debaisieux et al., 2012</xref>; <xref ref-type="bibr" rid="B53">Zeitler et al., 2015</xref>; <xref ref-type="bibr" rid="B1">Agostini et al., 2017</xref>; <xref ref-type="bibr" rid="B16">Katsinelos et al., 2018</xref>; <xref ref-type="bibr" rid="B22">Merezhko et al., 2018</xref>). In addition, certain aspects of this process may also be relevant to the unconventional secretory mechanism of interleukin 1<italic>&#x3b2;</italic>, a process that, under certain physiological conditions, is based upon the formation of membrane pores that are triggered by PI(4,5)P<sub>2</sub>-dependent oligomerization of inflammasome-activated Gasdermin D (<xref ref-type="bibr" rid="B14">He et al., 2015</xref>; <xref ref-type="bibr" rid="B21">Mart&#xed;n-S&#xe1;nchez et al., 2016</xref>; <xref ref-type="bibr" rid="B6">Brough et al., 2017</xref>; <xref ref-type="bibr" rid="B11">Evavold et al., 2017</xref>; <xref ref-type="bibr" rid="B23">Monteleone et al., 2018</xref>).</p>
</sec>
<sec id="s1-2">
<title>Recent Evidence Suggesting Liquid-Ordered Nanodomains to Play a Role in Organizing the Molecular Machinery Mediating FGF2 Membrane Translocation</title>
<p>The molecular principles of the unconventional secretory pathway of FGF2 could be recapitulated recently by two complementary experimental approaches, the biochemical reconstitution of FGF2 membrane translocation using purified components and giant unilamellar vesicles (GUVs) (<xref ref-type="bibr" rid="B43">Steringer et al., 2017</xref>) as well as the real-time imaging of FGF2 membrane translocation in living cells using single molecule TIRF microscopy (<xref ref-type="bibr" rid="B8">Dimou et al., 2019</xref>). In these studies, the molecular mechanism of this process has been validated and is now established in the field as the best-characterized example for a UPS Type I pathway (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref ref-type="bibr" rid="B9">Dimou and Nickel, 2018</xref>; <xref ref-type="bibr" rid="B34">Pallotta and Nickel, 2020</xref>). However, a striking difference was observed when comparing these experimental systems concerning the kinetics by which FGF2 can physically traverse the membrane. Using purified components to reconstitute FGF2 membrane translocation, incubation times in the range of several tens of minutes were required to observe a substantial amount of GUVs into which FGF2 had translocated (<xref ref-type="bibr" rid="B43">Steringer et al., 2017</xref>). Similar observations are made in experimental systems reconstituting PI(4,5)P<sub>2</sub>-dependent FGF2 oligomerization and membrane insertion (<xref ref-type="bibr" rid="B44">Steringer et al., 2012</xref>). By contrast, the time interval required for FGF2 translocation from the inner to the outer leaflet of the plasma membrane in living cells was found to be in the range of 200 ms (<xref ref-type="bibr" rid="B8">Dimou et al., 2019</xref>). Thus, whereas the molecular requirements were found to be identical with PI(4,5)P<sub>2</sub>-dependent oligomerization and heparan sulfate-mediated capturing of FGF2 being essential for FGF2 membrane translocation in both experimental systems, a vast difference was observed with regard to kinetics. Most likely, several factors contribute to this phenomenon. For example, in the biochemical reconstitution system, PI(4,5)P<sub>2</sub> is not present in an asymmetric distribution between the two leaflets that characterizes native plasma membranes. Further, whereas heparan sulfate chains on cell surfaces are contained in proteoglycans positioning them in a membrane-proximal manner, soluble heparin was added to the lumen of GUVs in reconstitution experiments (<xref ref-type="bibr" rid="B43">Steringer et al., 2017</xref>). Finally, auxiliary factors, such as the Na, K-ATPase, and Tec kinase, were absent in the <italic>in vitro</italic> reconstitution experiments. Whereas these factors probably affect the kinetics of FGF2 membrane translocation, they are unlikely to fully explain the vast difference of minutes versus milliseconds observed for this process when <italic>in vitro</italic> conditions (<xref ref-type="bibr" rid="B44">Steringer et al., 2012</xref>; <xref ref-type="bibr" rid="B43">Steringer et al., 2017</xref>) were compared with the authentic action observed in living cells (<xref ref-type="bibr" rid="B8">Dimou et al., 2019</xref>). What could be a compelling and testable explanation for the observed differences? An intriguing hypothesis would be the existence of nanodomains in native plasma membranes in which all components of the FGF2 secretion machinery are brought into proximity. As detailed below, recent studies indeed provide initial evidence for the structural organization of the FGF2 secretion machinery in specialized plasma membrane nanodomains.</p>
</sec>
<sec id="s1-3">
<title>A Role for Liquid-Ordered Nanodomains as a Structural Platform of the FGF2 Secretion Machinery?</title>
<p>Several lines of evidence support the idea of a subpopulation of liquid-ordered membrane domains enriched in cholesterol and PI(4,5)P<sub>2</sub> as platforms that host the machinery mediating FGF2 membrane translocation. First, in a recent study, cholesterol is demonstrated to be a critical factor affecting the ability of FGF2 to get recruited to membranes in a PI(4,5)P<sub>2</sub>-dependent manner with high binding strength and fast kinetics (<xref ref-type="bibr" rid="B19">Lolicato et al., 2021</xref>). The physiological relevance of this phenomenon could be confirmed in intact cells with increased levels of cholesterol resulting in higher efficiencies of FGF2 transport into the extracellular space. This study further provides insights into the molecular mechanism by which cholesterol affects both PI(4,5)P<sub>2</sub>-dependent recruitment and membrane translocation of FGF2 using molecular dynamics simulations. An increase of cholesterol at the expense of phosphatidylcholine, a scenario that mimics the changes in membrane lipid compositions when plasma membranes are compared with the endoplasmic reticulum, caused two phenomena. First, the visibility of the head group of PI(4,5)P<sub>2</sub> was found to be increased, facilitating FGF2 binding to lipid bilayers. Second, in the presence of increased levels of cholesterol, PI(4,5)P<sub>2</sub> was found to cluster forming trimers and tetramers. This, in turn, causes an increase in avidity, explaining faster binding kinetics and an enhanced binding strength of FGF2 toward PI(4,5)P<sub>2</sub> (<xref ref-type="bibr" rid="B19">Lolicato et al., 2021</xref>). The observed effects of cholesterol could also be directly relevant for the subsequent oligomerization of FGF2. Using molecular dynamics simulations, it was found that cholesterol-containing membranes stabilize an orientation of PI(4,5)P<sub>2</sub> that promotes the formation of disulfide-linked dimers of FGF2 (<xref ref-type="bibr" rid="B43">Steringer et al., 2017</xref>). Under these conditions, in addition to the defined high-affinity PI(4,5)P<sub>2</sub> binding site in FGF2, additional PI(4,5)P<sub>2</sub> molecules were found to bind to FGF2 at other sites. The role of PI(4,5)P<sub>2</sub> in this process is a highly specific one as artificial membrane anchors, such as a Ni-NTA lipid along with a His-tagged version of FGF2, were found incapable of forming functional FGF2 oligomers that form lipidic membrane pores as transient intermediates in unconventional secretion of FGF2 (<xref ref-type="bibr" rid="B44">Steringer et al., 2012</xref>; <xref ref-type="bibr" rid="B43">Steringer et al., 2017</xref>). Beyond the abovementioned studies on FGF2, an enrichment of PI(4,5)P<sub>2</sub> in liquid-ordered domains organized by cholesterol has indeed been recognized in other studies as well (<xref ref-type="bibr" rid="B26">Myeong et al., 2021</xref>; <xref ref-type="bibr" rid="B50">Wen et al., 2021</xref>).</p>
<p>Another recent study added further support to the idea that FGF2 membrane translocation occurs in cholesterol-enriched plasma membrane nanodomains characterized by a liquid-ordered state. In a BioID screen probing for proteins that are in proximity of FGF2 at any time point of its lifetime in cells, a specific type of heparan sulfate proteoglycan has been identified as the key driver of FGF2 secretion, Glypican-1 (GPC1) (<xref ref-type="bibr" rid="B42">Sparn et al., 2021</xref>). Whereas a knockout of GPC-1 was found to cause a substantial decrease in FGF2 secretion efficiencies, overexpression of GPC1 did not only rescue to wild-type levels but rather significantly increased FGF2 secretion rates. Furthermore, biochemical analyses revealed that the heparan sulfate chains of GPC1 contain high-affinity sites for FGF2 that are less present in other heparan sulfate proteoglycans, including members of the glypican and syndecan families. Of note, like all glypicans, GPC1 is associated with the outer leaflet of the plasma membrane <italic>via</italic> a GPI anchor (<xref ref-type="bibr" rid="B12">Filmus et al., 2008</xref>). Like other membrane proteins with GPI anchors, GPC1 is known to partition into liquid-ordered plasma membrane domains on cell surfaces. In addition, GPC1 contains a large N-terminal domain that builds a lid-like structure with a length of about 10&#xa0;nm on top of the membrane. The N-terminal lid domain is connected to the GPI anchor <italic>via</italic> a linker to which three heparan sulfate chains are attached. They are oriented in a highly membrane-proximal manner with the distance between them and the membrane surface being just about 3&#xa0;nm. These observations imply that the prominent role of GPC1 in unconventional secretion of FGF2 is promoted by its unique structure that appears to form a microenvironment between the GPC1 lid and the membrane surface in which high-affinity binding sites for FGF2 are arranged in a membrane-proximal and highly concentrated manner.</p>
</sec>
</sec>
<sec sec-type="discussion" id="s2">
<title>Discussion</title>
<p>Whereas the principal molecular components and mechanisms of the molecular machinery mediating unconventional secretion of FGF2 have been identified, its spatiotemporal organization at the plasma membrane is unknown. With recent findings demonstrating a role for cholesterol promoting efficient binding of FGF2 to PI(4,5)P<sub>2</sub> concomitant with increased FGF2 secretion rates, the identification of PI(4,5)P<sub>2</sub> clusters in liquid-ordered domains and the identification of GPC1, a GPI-anchored heparan sulfate proteoglycan that partitions into liquid-ordered domains, being the key driver of the unconventional secretory pathway of FGF2, we propose all components of this pathway to reside in plasma membrane nanodomains in a highly organized manner. It will be of great interest to challenge this hypothesis further, in particular with regard to the Na, K-ATPase that is the initial contact point for FGF2 at the inner plasma membrane leaflet. It will be an important future goal to reconstitute this type of nanodomain with purified components to uncover the mechanisms underlying the vast kinetic differences that have been found between <italic>in vitro</italic> reconstitution experiments and the authentic action observed in living cells. A comprehensive understanding of this pathway will not only solve a long-standing problem in molecular cell biology, but will also pave the way for the development of new inhibitors that have great potential for cancer therapy, for example, in fighting chemoresistances that are caused by FGF2 in acute myeloid leukemia.</p>
</sec>
</body>
<back>
<sec id="s3">
<title>Author Contributions</title>
<p>FL and WN: Conceptual design, development of hypotheses and writing the manuscript.</p>
</sec>
<sec id="s4">
<title>Funding</title>
<p>Deutsche Forschungsgemeinschaft (SFB/TRR 83, SFB/TRR 186, DFG Ni 423 / 9-1, DFG Ni 423 / 10-1, DFG Ni 423 / 12-1).</p>
</sec>
<sec sec-type="COI-statement" id="s5">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s6">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agostini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Vardabasso</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fittipaldi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tasciotti</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cereseto</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Inhibition of Non Canonical HIV-1 Tat Secretion through the Cellular Na &#x2b; ,K &#x2b; -ATPase Blocks HIV-1 Infection</article-title>. <source>EBioMedicine</source> <volume>21</volume>, <fpage>170</fpage>&#x2013;<lpage>181</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2017.06.011</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akl</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Nagpal</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ayoub</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Prabhu</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Capac</surname>
<given-names>C. M.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Molecular and Clinical Significance of Fibroblast Growth Factor 2 (FGF2/bFGF) in Malignancies of Solid and Hematological Cancers for Personalized Therapies</article-title>. <source>Oncotarget</source> <volume>7</volume>, <fpage>44735</fpage>&#x2013;<lpage>44762</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.8203</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Backhaus</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zehe</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wegehingel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kehlenbach</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schwappach</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Nickel</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Unconventional Protein Secretion: Membrane Translocation of FGF-2 Does Not Require Protein Unfolding</article-title>. <source>J. Cel Sci</source> <volume>117</volume>, <fpage>1727</fpage>&#x2013;<lpage>1736</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.01027</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beenken</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mohammadi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>The FGF Family: Biology, Pathophysiology and Therapy</article-title>. <source>Nat. Rev. Drug Discov.</source> <volume>8</volume>, <fpage>235</fpage>&#x2013;<lpage>253</lpage>. <pub-id pub-id-type="doi">10.1038/nrd2792</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belov</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Mohammadi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Molecular Mechanisms of Fibroblast Growth Factor Signaling in Physiology and Pathology</article-title>. <source>Cold Spring Harb Perspect. Biol.</source> <volume>5</volume>, <fpage>a015958</fpage>. <pub-id pub-id-type="doi">10.1101/cshperspect.a015958</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brough</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pelegrin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nickel</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>An Emerging Case for Membrane Pore Formation as a Common Mechanism for the Unconventional Secretion of FGF2 and IL-1&#x3b2;</article-title>. <source>J. Cel Sci</source> <volume>130</volume>, <fpage>3197</fpage>&#x2013;<lpage>3202</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.204206</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Debaisieux</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rayne</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yezid</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Beaumelle</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>The Ins and Outs of HIV-1 Tat</article-title>. <source>Traffic</source> <volume>13</volume>, <fpage>355</fpage>&#x2013;<lpage>363</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0854.2011.01286.x</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dimou</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cosentino</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Platonova</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ros</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Sadeghi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kashyap</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Single Event Visualization of Unconventional Secretion of FGF2</article-title>. <source>J. Cel Biol</source> <volume>218</volume> (<issue>2</issue>), <fpage>683</fpage>&#x2013;<lpage>699</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.201802008</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dimou</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nickel</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Unconventional Mechanisms of Eukaryotic Protein Secretion</article-title>. <source>Curr. Biol.</source> <volume>28</volume>, <fpage>R406</fpage>&#x2013;<lpage>R410</lpage>. <pub-id pub-id-type="doi">10.1016/j.cub.2017.11.074</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ebert</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Laussmann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wegehingel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kaderali</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Erfle</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Reichert</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Tec-kinase-mediated Phosphorylation of Fibroblast Growth Factor 2 Is Essential for Unconventional Secretion</article-title>. <source>Traffic</source> <volume>11</volume>, <fpage>813</fpage>&#x2013;<lpage>826</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0854.2010.01059.x</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evavold</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kagan</surname>
<given-names>J. C.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The Pore-Forming Protein Gasdermin D Regulates Interleukin-1 Secretion from Living Macrophages</article-title>. <source>Immunity</source> <volume>48</volume> (<issue>1</issue>), <fpage>35</fpage>&#x2013;<lpage>44.e6</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2017.11.013</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filmus</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Capurro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rast</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Glypicans</article-title>. <source>Genome Biol.</source> <volume>9</volume>, <fpage>224</fpage>. <pub-id pub-id-type="doi">10.1186/gb-2008-9-5-224</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilbert</surname>
<given-names>R. J. C.</given-names>
</name>
<name>
<surname>Serra</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Froelich</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Wallace</surname>
<given-names>M. I.</given-names>
</name>
<name>
<surname>Anderluh</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Membrane Pore Formation at Protein-Lipid Interfaces</article-title>. <source>Trends Biochem. Sci.</source> <volume>39</volume>, <fpage>510</fpage>&#x2013;<lpage>516</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2014.09.002</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>W.-t.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Gasdermin D Is an Executor of Pyroptosis and Required for Interleukin-1&#x3b2; Secretion</article-title>. <source>Cell Res</source> <volume>25</volume>, <fpage>1285</fpage>&#x2013;<lpage>1298</lpage>. <pub-id pub-id-type="doi">10.1038/cr.2015.139</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Javidi-Sharifi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>English</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Joshi</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Scopim-Ribeiro</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Viola</surname>
<given-names>S. K.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>FGF2-FGFR1 Signaling Regulates Release of Leukemia-Protective Exosomes from Bone Marrow Stromal Cells</article-title>. <source>Elife</source> <volume>8</volume>, <fpage>e40033</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.40033</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katsinelos</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zeitler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dimou</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Karakatsani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>M&#xfc;ller</surname>
<given-names>H.-M.</given-names>
</name>
<name>
<surname>Nachman</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Unconventional Secretion Mediates the Trans-cellular Spreading of Tau</article-title>. <source>Cel Rep.</source> <volume>23</volume>, <fpage>2039</fpage>&#x2013;<lpage>2055</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2018.04.056</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>La Venuta</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wegehingel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sehr</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>M&#xfc;ller</surname>
<given-names>H.-M.</given-names>
</name>
<name>
<surname>Dimou</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Steringer</surname>
<given-names>J. P.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Small Molecule Inhibitors Targeting Tec Kinase Block Unconventional Secretion of Fibroblast Growth Factor 2</article-title>. <source>J. Biol. Chem.</source> <volume>291</volume>, <fpage>17787</fpage>&#x2013;<lpage>17803</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m116.729384</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Legrand</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Saleppico</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sticht</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lolicato</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>M&#xfc;ller</surname>
<given-names>H.-M.</given-names>
</name>
<name>
<surname>Wegehingel</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The Na,K-ATPase Acts Upstream of Phosphoinositide PI(4,5)P2 Facilitating Unconventional Secretion of Fibroblast Growth Factor 2</article-title>. <source>Commun. Biol.</source> <volume>3</volume>, <fpage>141</fpage>. <pub-id pub-id-type="doi">10.1038/s42003-020-0871-y</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lolicato</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Saleppico</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Griffo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pokrandt</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>M&#xfc;ller</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Ewers</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Cholesterol Promotes Both Head Group Visibility and Clustering of PI(4,5)P2 Driving Unconventional Secretion of Fibroblast Growth Factor 2</article-title>. <source>bioRxiv</source>. <pub-id pub-id-type="doi">10.1101/2021.04.16.440132</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malhotra</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Unconventional Protein Secretion: an Evolving Mechanism</article-title>. <source>EMBO J.</source> <volume>32</volume>, <fpage>1660</fpage>&#x2013;<lpage>1664</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2013.104</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mart&#xed;n-S&#xe1;nchez</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Diamond</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zeitler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>A. I.</given-names>
</name>
<name>
<surname>Baroja-Mazo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bagnall</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Inflammasome-dependent IL-1&#x3b2; Release Depends upon Membrane Permeabilisation</article-title>. <source>Cell Death Differ</source> <volume>23</volume>, <fpage>1219</fpage>&#x2013;<lpage>1231</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2015.176</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merezhko</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Brunello</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Vihinen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jokitalo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Uronen</surname>
<given-names>R.-L.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Secretion of Tau via an Unconventional Non-vesicular Mechanism</article-title>. <source>Cel Rep.</source> <volume>25</volume>, <fpage>2027</fpage>&#x2013;<lpage>2035</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2018.10.078</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monteleone</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Stanley</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K. W.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Bezbradica</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>von Pein</surname>
<given-names>J. B.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Interleukin-1&#x3b2; Maturation Triggers its Relocation to the Plasma Membrane for Gasdermin-D-dependent and -Independent Secretion</article-title>. <source>Cel Rep.</source> <volume>24</volume>, <fpage>1425</fpage>&#x2013;<lpage>1433</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2018.07.027</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muesch</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hartmann</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rohde</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rubartelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sitia</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rapoport</surname>
<given-names>T. A.</given-names>
</name>
</person-group> (<year>1990</year>). <article-title>A Novel Pathway for Secretory Proteins?</article-title> <source>Trends Biochem. Sci.</source> <volume>15</volume>, <fpage>86</fpage>&#x2013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/0968-0004(90)90186-f</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>M&#xfc;ller</surname>
<given-names>H.-M.</given-names>
</name>
<name>
<surname>Steringer</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Wegehingel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bleicken</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>M&#xfc;nster</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dimou</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Formation of Disulfide Bridges Drives Oligomerization, Membrane Pore Formation, and Translocation of Fibroblast Growth Factor 2 to Cell Surfaces</article-title>. <source>J. Biol. Chem.</source> <volume>290</volume>, <fpage>8925</fpage>&#x2013;<lpage>8937</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m114.622456</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Myeong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>C. G.</given-names>
</name>
<name>
<surname>Suh</surname>
<given-names>B. C.</given-names>
</name>
<name>
<surname>Hille</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Compartmentalization of Phosphatidylinositol 4,5-bisphosphate Metabolism into Plasma Membrane Liquid-Ordered/raft Domains</article-title>. <source>Proc. Natl. Acad. Sci. U S A.</source> <volume>118</volume>. <pub-id pub-id-type="doi">10.1073/pnas.2025343118</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nickel</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Rabouille</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Mechanisms of Regulated Unconventional Protein Secretion</article-title>. <source>Nat. Rev. Mol. Cel Biol</source> <volume>10</volume>, <fpage>148</fpage>&#x2013;<lpage>155</lpage>. <pub-id pub-id-type="doi">10.1038/nrm2617</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nickel</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Seedorf</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Unconventional Mechanisms of Protein Transport to the Cell Surface of Eukaryotic Cells</article-title>. <source>Annu. Rev. Cel Dev. Biol.</source> <volume>24</volume>, <fpage>287</fpage>&#x2013;<lpage>308</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.cellbio.24.110707.175320</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nickel</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>The Mystery of Nonclassical Protein Secretion</article-title>. <source>Eur. J. Biochem.</source> <volume>270</volume>, <fpage>2109</fpage>&#x2013;<lpage>2119</lpage>. <pub-id pub-id-type="doi">10.1046/j.1432-1033.2003.03577.x</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nickel</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>The Unconventional Secretory Machinery of Fibroblast Growth Factor 2</article-title>. <source>Traffic</source> <volume>12</volume>, <fpage>799</fpage>&#x2013;<lpage>805</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0854.2011.01187.x</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nickel</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Unconventional Secretion: an Extracellular Trap for export of Fibroblast Growth Factor 2</article-title>. <source>J. Cel Sci</source> <volume>120</volume>, <fpage>2295</fpage>&#x2013;<lpage>2299</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.011080</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noh</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.-H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>K.-H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.-H.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>T. H.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>API5 Confers Tumoral Immune Escape through FGF2-dependent Cell Survival Pathway</article-title>. <source>Cancer Res.</source> <volume>74</volume>, <fpage>3556</fpage>&#x2013;<lpage>3566</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.can-13-3225</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nugent</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Iozzo</surname>
<given-names>R. V.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Fibroblast Growth Factor-2</article-title>. <source>Int. J. Biochem. Cel Biol.</source> <volume>32</volume>, <fpage>115</fpage>&#x2013;<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1016/s1357-2725(99)00123-5</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pallotta</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Nickel</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>FGF2 and IL-1&#x3b2; - Explorers of Unconventional Secretory Pathways at a Glance</article-title>. <source>J. Cel Sci</source> <volume>133</volume>. <pub-id pub-id-type="doi">10.1242/jcs.250449</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plotnikov</surname>
<given-names>A. N.</given-names>
</name>
<name>
<surname>Schlessinger</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hubbard</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Mohammadi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Structural Basis for FGF Receptor Dimerization and Activation</article-title>. <source>Cell</source> <volume>98</volume>, <fpage>641</fpage>&#x2013;<lpage>650</lpage>. <pub-id pub-id-type="doi">10.1016/s0092-8674(00)80051-3</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Presta</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dell&#x2019;Era</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mitola</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Moroni</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ronca</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rusnati</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Fibroblast Growth Factor/fibroblast Growth Factor Receptor System in Angiogenesis</article-title>. <source>Cytokine Growth Factor. Rev.</source> <volume>16</volume>, <fpage>159</fpage>&#x2013;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1016/j.cytogfr.2005.01.004</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rabouille</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Pathways of Unconventional Protein Secretion</article-title>. <source>Trends Cel Biol.</source> <volume>27</volume>, <fpage>230</fpage>&#x2013;<lpage>240</lpage>. <pub-id pub-id-type="doi">10.1016/j.tcb.2016.11.007</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Venkataraman</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ernst</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sasisekharan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Sasisekharan</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Structural Specificity of Heparin Binding in the Fibroblast Growth Factor Family of Proteins</article-title>. <source>Proc. Natl. Acad. Sci.</source> <volume>100</volume>, <fpage>2357</fpage>&#x2013;<lpage>2362</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0437842100</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rayne</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Debaisieux</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yezid</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.-L.</given-names>
</name>
<name>
<surname>Mettling</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Konate</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Phosphatidylinositol-(4,5)-bisphosphate Enables Efficient Secretion of HIV-1 Tat by Infected T-Cells</article-title>. <source>EMBO J.</source> <volume>29</volume>, <fpage>1348</fpage>&#x2013;<lpage>1362</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2010.32</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ribatti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Vacca</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rusnati</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Presta</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>The Discovery of Basic Fibroblast Growth Factor/fibroblast Growth Factor-2 and its Role in Haematological Malignancies</article-title>. <source>Cytokine Growth Factor. Rev.</source> <volume>18</volume>, <fpage>327</fpage>&#x2013;<lpage>334</lpage>. <pub-id pub-id-type="doi">10.1016/j.cytogfr.2007.04.011</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schlessinger</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Plotnikov</surname>
<given-names>A. N.</given-names>
</name>
<name>
<surname>Ibrahimi</surname>
<given-names>O. A.</given-names>
</name>
<name>
<surname>Eliseenkova</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>B. K.</given-names>
</name>
<name>
<surname>Yayon</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>). <article-title>Crystal Structure of a Ternary FGF-FGFR-Heparin Complex Reveals a Dual Role for Heparin in FGFR Binding and Dimerization</article-title>. <source>Mol. Cel</source> <volume>6</volume>, <fpage>743</fpage>&#x2013;<lpage>750</lpage>. <pub-id pub-id-type="doi">10.1016/s1097-2765(00)00073-3</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sparn</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dimou</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Saleppico</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wegehingel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gerstner</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Glypican-1 Drives Unconventional Secretion of Fibroblast Growth Factor 2</article-title>. <source>bioRxiv</source>. <pub-id pub-id-type="doi">10.1101/2021.11.11.468179</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steringer</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Lange</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>&#x10c;ujov&#xe1;</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>&#x160;achl</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Poojari</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lolicato</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Key Steps in Unconventional Secretion of Fibroblast Growth Factor 2 Reconstituted with Purified Components</article-title>. <source>Elife</source> <volume>6</volume>, <fpage>e28985</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.28985</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steringer</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Bleicken</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Andreas</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zacherl</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Laussmann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Temmerman</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Phosphatidylinositol 4,5-Bisphosphate (PI(4,5)P2)-dependent Oligomerization of Fibroblast Growth Factor 2 (FGF2) Triggers the Formation of a Lipidic Membrane Pore Implicated in Unconventional Secretion</article-title>. <source>J. Biol. Chem.</source> <volume>287</volume>, <fpage>27659</fpage>&#x2013;<lpage>27669</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m112.381939</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steringer</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Nickel</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>A Direct Gateway into the Extracellular Space: Unconventional Secretion of FGF2 through Self-Sustained Plasma Membrane Pores</article-title>. <source>Semin. Cel. Dev. Biol.</source> <volume>83</volume>, <fpage>3</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcdb.2018.02.010</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Temmerman</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ebert</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>M&#xfc;ller</surname>
<given-names>H.-M.</given-names>
</name>
<name>
<surname>Sinning</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Tews</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Nickel</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>A Direct Role for Phosphatidylinositol-4,5-Bisphosphate in Unconventional Secretion of Fibroblast Growth Factor 2</article-title>. <source>Traffic</source> <volume>9</volume>, <fpage>1204</fpage>&#x2013;<lpage>1217</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0854.2008.00749.x</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Temmerman</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nickel</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>A Novel Flow Cytometric Assay to Quantify Interactions between Proteins and Membrane Lipids</article-title>. <source>J. Lipid Res.</source> <volume>50</volume>, <fpage>1245</fpage>&#x2013;<lpage>1254</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.d800043-jlr200</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torrado</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>Temmerman</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mu&#x308;ller</surname>
<given-names>H.-M.</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Seelenmeyer</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Backhaus</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>An Intrinsic Quality-Control Mechanism Ensures Unconventional Secretion of Fibroblast Growth Factor 2 in a Folded Conformation</article-title>. <source>J. Cel Sci</source> <volume>122</volume>, <fpage>3322</fpage>&#x2013;<lpage>3329</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.049791</pub-id> </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Traer</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Javidi-Sharifi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Agarwal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dunlap</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>English</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia</article-title>. <source>Cancer Res.</source> <volume>76</volume>, <fpage>6471</fpage>&#x2013;<lpage>6482</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.can-15-3569</pub-id> </citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Vogt</surname>
<given-names>V. M.</given-names>
</name>
<name>
<surname>Feigenson</surname>
<given-names>G. W.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>PI(4,5)P2 Clustering and its Impact on Biological Functions</article-title>. <source>Annu. Rev. Biochem.</source> <volume>90</volume>, <fpage>681</fpage>&#x2013;<lpage>707</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-biochem-070920-094827</pub-id> </citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zacherl</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>La Venuta</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>M&#xfc;ller</surname>
<given-names>H.-M.</given-names>
</name>
<name>
<surname>Wegehingel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dimou</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sehr</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>A Direct Role for ATP1A1 in Unconventional Secretion of Fibroblast Growth Factor 2</article-title>. <source>J. Biol. Chem.</source> <volume>290</volume>, <fpage>3654</fpage>&#x2013;<lpage>3665</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m114.590067</pub-id> </citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zehe</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Engling</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wegehingel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schafer</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nickel</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Cell-surface Heparan Sulfate Proteoglycans Are Essential Components of the Unconventional export Machinery of FGF-2</article-title>. <source>Proc. Natl. Acad. Sci.</source> <volume>103</volume>, <fpage>15479</fpage>&#x2013;<lpage>15484</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0605997103</pub-id> </citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeitler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Steringer</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>M&#xfc;ller</surname>
<given-names>H.-M.</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Nickel</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>HIV-tat Protein Forms Phosphoinositide-dependent Membrane Pores Implicated in Unconventional Protein Secretion</article-title>. <source>J. Biol. Chem.</source> <volume>290</volume>, <fpage>21976</fpage>&#x2013;<lpage>21984</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m115.667097</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>